Mostrar el registro sencillo del ítem

dc.contributor.authorBurgos López, Y.
dc.contributor.authorPlá, Julián del
dc.contributor.authorBalsa, Lucía M.
dc.contributor.authorLeón, Ignacio E.
dc.contributor.authorEcheverría, Gustavo A.
dc.contributor.authorPiro, Oscar Enrique
dc.contributor.authorGarcía Tojal, Javier 
dc.contributor.authorPis Diez, Reinaldo
dc.contributor.authorGonzález Baró, Ana C.
dc.contributor.authorParajón Costa, Beatriz S.
dc.date.accessioned2019-04-29T07:56:06Z
dc.date.issued2019-03
dc.identifier.issn0020-1693
dc.identifier.urihttp://hdl.handle.net/10259/5085
dc.description.abstractThe new copper complex, [Cu(HL)(OH2)2](NO3), including the tridentate N-acyhydrazone derived from 4-hydroxy-benzohydrazide and 2-hydroxy-3-methoxybenzaldehyde, (H2L), has been synthesized and characterized in the solid state and in solution by spectroscopic (FTIR, Ra, UV–vis, EPR) methods. The results were compared with those obtained for the hydrazone ligand and complemented with computational methods based on DFT. The crystal structure of the complex has been determined by X-ray diffraction. It crystallizes in the triclinic space group with Z = 2. The Cu(II) ion is in a distorted square pyramidal environment, coordinated to a planar HL- anion acting as a tridentate ligand. The 5-fold coordination is completed with two water molecules. It is arranged in the lattice as H-bonded ribbon-like polymers that extends along the [1 2 1] crystal direction. The cytotoxicity of the complex together with that of the H2L ligand and the copper ion were evaluated in vitro against five different human cancer cell lines namely A549 (lung), MG-63 (bone), MCF-7 and MDA-MB-231 (breast) and Jurkat (leukemia). The copper complex inhibits the cell viability in a dose dependent manner with a greater potency than the H2L ligand and the free copper ion displaying even higher antitumor activity than the well-known anticancer metallodrug cisplatin.en
dc.description.sponsorshipCONICET (PIP 11220130100651CO and PIP 0034), UNLP (111/X673) and ANPCyT (PICT 2014-2223) of Argentina. Consejería de Educación CyL and FFEDER BU076U16, BU022G18 and Ministerio de Economía y Competitividad CTQ2016-75023-C2-1-P and CTQ2015-70371-REDTMetDrugs Network (Spain)en
dc.format.mimetypeapplication/pdf
dc.language.isoenges
dc.publisherElsevieren
dc.relation.ispartofInorganica Chimica Acta. 2019, V. 487, p. 31-40en
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCu(II)-complexen
dc.subjectHydrazonesen
dc.subjectSpectroscopyen
dc.subjectCrystal structureen
dc.subjectDFT calculationsen
dc.subjectAnticancer activityen
dc.subject.otherQuímica inorgánicaes
dc.subject.otherChemistry, Inorganicen
dc.titleSynthesis, crystal structure and cytotoxicity assays of a copper(II) nitrate complex with a tridentate ONO acylhydrazone ligand. Spectroscopic and theoretical studies of the complex and its liganden
dc.typeinfo:eu-repo/semantics/article
dc.date.embargo2021-03-01
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.relation.publisherversionhttps://doi.org/10.1016/j.ica.2018.11.039
dc.identifier.doi10.1016/j.ica.2018.11.039
dc.relation.projectIDinfo:eu-repo/grantAgreement/JCyL/BU076U16
dc.relation.projectIDinfo:eu-repo/grantAgreement/JCyL/BU022G18
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO/CTQ2016-75023-C2-1-P
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO/CTQ2015-70371-REDTMetDrugs
dc.relation.projectIDinfo:eu-repo/grantAgreement/CONICET/PIP 11220130100651CO
dc.relation.projectIDinfo:eu-repo/grantAgreement/CONICET/PIP 0034
dc.relation.projectIDinfo:eu-repo/grantAgreement/UNLP/111-X673
dc.relation.projectIDinfo:eu-repo/grantAgreement/ANPCyT/PICT 2014-2223
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersion


Ficheros en este ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem